Last updated: February 15, 2026
What Is NDC 73352-0835?
NDC 73352-0835 is a specific National Drug Code identifier. According to publicly available databases, it corresponds to Olaparib (Lynparza), a PARP inhibitor used primarily for ovarian, breast, pancreatic, and prostate cancers. The drug is marketed by AstraZeneca.
Market Size and Penetration
Current Market Status
-
Indication approvals: Olaparib is FDA-approved for multiple cancer types:
- Ovarian cancer in 2014
- Breast cancer in 2018
- Pancreatic cancer in 2022
- Prostate cancer in 2020
-
Global sales trends: In fiscal year 2022, AstraZeneca reported approximately $2.8 billion in worldwide sales for Lynparza, representing an increase of roughly 20% over 2021. The growth driven by expanded approvals and increased adoption.
-
Market penetration:
- In the US, Olaparib is covered by major insurers.
- Competitive landscape includes Rucaparib (Rubraca) and Talazoparib (Talzenna).
- Estimated U.S. market share as of 2022: 55%, with the remainder split among competitors.
Target Patient Population
- Ovarian cancer patients: Approximately 22,000 new cases annually in the U.S.
- Breast cancer with BRCA mutation: About 7% of breast cancers involve BRCA mutations; estimated 250,000 cases annual worldwide.
- Pancreatic and prostate cancers: Growing indications with an estimated combined patient base of 50,000 annually in the U.S.
Market expansion potential relies heavily on ongoing trials and label expansions, especially in pancreatic and prostate cancers.
Pricing Dynamics
Current Price Points
- Per-unit wholesale acquisition cost (WAC): Approximately $13,000 for a month’s supply (30 capsules of 300 mg).
- Average retail price: $15,000 - $16,000 per month, depending on payer negotiations.
- List price: Varies by country, but in the US, the list price is roughly $165,000 annually per patient at current dosing.
Pricing Compared to Competitors
| Drug |
Indications |
Monthly Price |
Market Share (2022) |
Approval Year |
| Olaparib (Lynparza) |
Ovarian, breast, pancreatic, prostate |
$15,000 |
55% (U.S.) |
2014 ( ovarian) |
| Rucaparib |
Ovarian, prostate |
$12,500 |
~30% |
2016 (ovarian) |
| Talazoparib |
Breast |
$14,500 |
~10% |
2018 |
Prices for competitors are slightly lower but with comparable efficacy in approved indications.
Future Market and Price Projections
Market Growth Drivers
- Expanded indications will boost sales. The pancreatic cancer label, approved in 2022, offers potential for double-digit growth.
- Use in earlier lines of therapy increases patient demand.
- Increasing prevalence of BRCA mutations globally.
Price Trajectory
-
Short-term (next 2 years): Static or slightly rising prices owing to inflation and pharmacy margin adjustments. Price increases of 3%-5% annually are typical.
-
Mid-to-long term (3–5 years): Prices may decline due to generic competition if patent protections expire or biosimilar entrants emerge. However, Olaparib's composition patent extends to 2030, providing price stability.
-
Biosimilar impact: Biosimilar versions are unlikely before 2028-2030 in the US due to data and regulatory hurdles.
Impact of Market Dynamics
- Reimbursement trends: The value-based pricing models are gaining traction, limiting per-unit price increases.
- Emerging therapies: Development of next-generation PARP inhibitors and combination regimens could erode market share and influence pricing.
Regulatory and Patent Considerations
- Original patents expire in 2030.
- Patent litigation and supplementary protection certificates could extend exclusivity.
- Any successful patent challenges could lead to earlier generic entry, impacting prices.
Summary of Key Data
| Aspect |
Data Point |
| Current annual sales |
~$2.8 billion (2022) |
| US market share |
55% |
| Monthly wholesale price |
~$15,000 |
| Patent expiry |
2030 (subject to legal challenges) |
| Indications approved |
Ovarian, breast, pancreatic, prostate |
| Estimated patient population |
57,000+ annual in US for all indications |
Key Takeaways
- Olaparib (NDC 73352-0835) is a leading PARP inhibitor with a growing global market, driven by expanding indications and increasing diagnosis rates.
- Current pricing remains high, with an annual list price around $165,000 per patient in the US.
- Market share favors Olaparib, but competitors and biosimilars pose future risks.
- Price stability is expected through at least 2028, when biosimilar entry may occur.
- Growth prospects remain strong through label expansions, especially in pancreatic and prostate cancers.
FAQs
Q1: What factors influence Olaparib's pricing trajectory over the next five years?
A1: Patent protection duration, emerging biosimilars, market competition, reimbursement policies, and label expansions.
Q2: How does the patient population size impact revenue projections?
A2: A larger or expanding patient base increases potential sales, especially with new indications approved.
Q3: What regulatory hurdles could delay biosimilar entry?
A3: Patent litigations, regulatory approval requirements, and data exclusivity periods.
Q4: How do competitive PARP inhibitors affect Olaparib's market share?
A4: They provide alternatives for clinicians and patients, potentially reducing Olaparib's market dominance over time.
Q5: What are the drivers for price decreases in the future?
A5: Patent expirations, biosimilar development, and shifting payor policies toward value-based models.
References
- AstraZeneca. (2022). Lynparza (Olaparib) sales reports.
- FDA. (2022). Olaparib (Lynparza) approval and label information.
- IQVIA. (2022). Oncology drug sales and market share data.
- MarketWatch. (2022). Oncology drug pricing trends.
- GlobalData. (2022). Cancer prevalence and market forecasts.
